These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 19952305)

  • 21. Comparison of the bleeding potential of vampire bat salivary plasminogen activator versus tissue plasminogen activator in an experimental rabbit model.
    Montoney M; Gardell SJ; Marder VJ
    Circulation; 1995 Mar; 91(5):1540-4. PubMed ID: 7867196
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting recombinant thrombomodulin fusion protein to red blood cells provides multifaceted thromboprophylaxis.
    Zaitsev S; Kowalska MA; Neyman M; Carnemolla R; Tliba S; Ding BS; Stonestrom A; Spitzer D; Atkinson JP; Poncz M; Cines DB; Esmon CT; Muzykantov VR
    Blood; 2012 May; 119(20):4779-85. PubMed ID: 22493296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. K1K2Pu, a recombinant t-PA/u-PA chimera with increased thrombolytic potency, consisting of amino acids 1 to 3 and 87 to 274 of human tissue-type plasminogen activator (t-PA) and amino acids 138 to 411 of human single chain urokinase-type plasminogen activator (scu-PA). Purification in centigram quantities and conditioning for use in man.
    Collen D; Nelles L; De Cock F; Lemmens G; Van Coetsem T; Demarsin E; Lijnen HR
    Thromb Res; 1992 Feb; 65(3):421-38. PubMed ID: 1631805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protein engineering of novel plasminogen activators with increased thrombolytic potency in rabbits relative to activase.
    Larsen GR; Timony GA; Horgan PG; Barone KM; Henson KS; Angus LB; Stoudemire JB
    J Biol Chem; 1991 May; 266(13):8156-61. PubMed ID: 1708773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator.
    Lijnen HR; Dewerchin M; De Cock F; Collen D
    Thromb Res; 1990 Feb; 57(3):333-42. PubMed ID: 2107593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Structure, function and use of fibrinolysis-promoting and inhibiting factors].
    Bachmann F
    Arzneimittelforschung; 1988 Mar; 38(3A):474-8. PubMed ID: 3134901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New strategies in the development of thrombolytic agents.
    Lijnen HR; Collen D
    Curr Stud Hematol Blood Transfus; 1991; (58):69-72. PubMed ID: 1954777
    [No Abstract]   [Full Text] [Related]  

  • 28. Delivery of anti-platelet-endothelial cell adhesion molecule single-chain variable fragment-urokinase fusion protein to the cerebral vasculature lyses arterial clots and attenuates postischemic brain edema.
    Danielyan K; Ding BS; Gottstein C; Cines DB; Muzykantov VR
    J Pharmacol Exp Ther; 2007 Jun; 321(3):947-52. PubMed ID: 17389242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect.
    Gurewich V; Pannell R
    Thromb Haemost; 1987 Jun; 57(3):372-3. PubMed ID: 3116707
    [No Abstract]   [Full Text] [Related]  

  • 30. Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model.
    Collen D; Dewerchin M; Rapold HJ; Lijnen HR; Stassen JM
    Circulation; 1990 Nov; 82(5):1744-53. PubMed ID: 2121385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular mechanism of action of newer thrombolytic agents.
    Collen D
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):11B-15B. PubMed ID: 3117858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting of organophosphorus compound bioscavengers to the surface of red blood cells.
    McCranor BJ; Hofstetter CA; Olert MA; Moorad-Doctor D; Cerasoli DM; Garcia GE
    Chem Biol Interact; 2016 Nov; 259(Pt B):205-210. PubMed ID: 27163849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Limited fibrin specificity of tissue-type plasminogen activator and its potential link to bleeding.
    Weitz JI
    J Vasc Interv Radiol; 1995; 6(6 Pt 2 Suppl):19S-23S. PubMed ID: 8770837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
    Sakharov DV; Barrertt-Bergshoeff M; Hekkenberg RT; Rijken DC
    Thromb Haemost; 1999 Apr; 81(4):605-12. PubMed ID: 10235448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thrombolytic profiles of clot-targeted plasminogen activators. Parameters determining potency and initial and maximal rates.
    Holvoet P; Dewerchin M; Stassen JM; Lijnen HR; Tollenaere T; Gaffney PJ; Collen D
    Circulation; 1993 Mar; 87(3):1007-16. PubMed ID: 8443877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biochemical and thrombolytic properties of a low molecular weight form (comprising Leu144 through Leu411) of recombinant single-chain urokinase-type plasminogen activator.
    Lijnen HR; Nelles L; Holmes WE; Collen D
    J Biol Chem; 1988 Apr; 263(12):5594-8. PubMed ID: 2965704
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of a recombinant chimeric plasminogen activator composed of a fibrin fragment-D-dimer-specific humanized monoclonal antibody and a truncated single-chain urokinase.
    Vandamme AM; Dewerchin M; Lijnen HR; Bernar H; Bulens F; Nelles L; Collen D
    Eur J Biochem; 1992 Apr; 205(1):139-46. PubMed ID: 1313361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thrombolytic agents in development.
    Verstraete M; Lijnen HR; Collen D
    Drugs; 1995 Jul; 50(1):29-42. PubMed ID: 7588087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cerebrovascular thromboprophylaxis in mice by erythrocyte-coupled tissue-type plasminogen activator.
    Danielyan K; Ganguly K; Ding BS; Atochin D; Zaitsev S; Murciano JC; Huang PL; Kasner SE; Cines DB; Muzykantov VR
    Circulation; 2008 Sep; 118(14):1442-9. PubMed ID: 18794394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Erythrocyte membrane proteins reactive with IgG (warm-reacting) anti-red blood cell autoantibodies: II. Antibodies coprecipitating band 3 and glycophorin A.
    Leddy JP; Wilkinson SL; Kissel GE; Passador ST; Falany JL; Rosenfeld SI
    Blood; 1994 Jul; 84(2):650-6. PubMed ID: 7517724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.